This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Wailoo AJ, Bansback N, Brennan A, Michaud K, Nixon RM, Wolfe F.Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis. Arthritis and Rheumatism 58: 939-946, No. 4, Apr 2008
About this article
Cite this article
Etanercept, adalimumab worth trying over infliximab for RA. Pharmacoecon. Outcomes News 554, 6 (2008). https://doi.org/10.2165/00151234-200805540-00013
- Rheumatoid Arthritis
- Good Choice
- Health Economic